Administration of liquid sublingual immunotherapy using the iPUMP: The real-life SPEED study - 28/04/26
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | What is already known about this topic? |
• | Allergen immunotherapy is often recommended for the treatment of allergy, but success is often limited due to compliance with administration procedures and the requirement for long-term adherence. |
• | What does this article add to our knowledge? |
• | A newly developed connected device, iPUMP, can enhance treatment administration adherence and persistence for sublingual immunotherapy, especially in children. Additionally, the iPUMP facilitates an autonomous approach and strengthens parents’ confidence that the treatment is applied correctly. |
• | How does this study impact current guidelines |
• | The validation study presented here provides real-world evidence that the iPUMP can help the delivery of sublingual immunotherapy for all ages, especially for children, by improving adherence and observance to treatment over the long term. |
Abstract |
Background and objectives |
Prior studies show that a small proportion of patients reach the recommended 3 years of treatment in allergen immunotherapy (AIT). Recently, a connected device (iPUMP®) was developed to enhance patient engagement and optimize treatment management of sublingual immunotherapy (SLIT). The SPEED study evaluated the impact of the iPUMP on treatment adherence and persistence and examined the long-term use of SLIT in real-life.
Methods |
The observational SPEED study consisted of two parts: a retrospective analysis to evaluate persistence, which tracked the renewal of SLIT treatment using 22,250 orders (representing 10,567 treatments) from the Stallergenes Greer database; and a prospective survey conducted from May 29 to November 29, 2024, recruiting 381 patients starting SLIT for cat or HDM allergy. Patients were grouped into an iPUMP cohort (n = 181) and a Standard Care cohort (n = 200). Questionnaire data were collected after 3 months of treatment. Descriptive statistics were used for analysis of both components of the study.
Results |
82% of patients using the iPUMP® renewed their SLIT treatment, compared to 67% of those who did not. The use of the iPUMP® consistently increased daily intake (consumption volumes) across all age groups. The connected device notably facilitated independence in younger patients. In the iPUMP® group, parental assistance decreased from 50% at initiation to 29% after 3 months, while in the standard care group, parental assistance increased in the same period (from 24% to 58%). Most parents (50%) felt perfectly reassured about SLIT delivery when using the iPUMP®, compared to 36% without the device. At treatment initiation, over 70% of users reported reassurance regarding proper dose delivery, timing, and pressure control. As a treatment support, 8 out of 10 users found the iPUMP® helpful. A majority of both younger (80% of 5–12-year-olds) and older (79% of those over 12) patients believed the iPUMP® was an aid and plan to use it.
Conclusions |
The study suggests a substantial impact of the iPUMP® on treatment renewal rates and treatment adherence, especially in younger patients. Consequently, it could be an effective tool to improve adherence to SLIT treatment by facilitating an autonomous approach and strengthening parents' confidence.
Le texte complet de cet article est disponible en PDF.Keywords : adherence, compliance, connected device, persistence, sublingual allergen immunotherapy (SLIT)
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.